Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Plaque Psoriasis BURLINGAME, CA, UNITED STATES, January 27, 2025 /EINPresswire / -- The worldwide Plaque Psoriasis <a target=_blank href=h ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...